Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 3 4 Next >
News headline image
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
From VALNEVA
Via GlobeNewswire
News headline image
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Participate at U.S. and European Investor Conferences in June
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
From VALNEVA
Via GlobeNewswire
News headline image
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
From VALNEVA
Via GlobeNewswire
News headline image
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
From VALNEVA
Via GlobeNewswire
News headline image
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
From VALNEVA
Via GlobeNewswire
News headline image
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
From VALNEVA
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.